180 related articles for article (PubMed ID: 12442990)
1. Assessing human health response in life cycle assessment using ED10s and DALYs: part 1--Cancer effects.
Crettaz P; Pennington D; Rhomberg L; Brand K; Jolliet O
Risk Anal; 2002 Oct; 22(5):931-46. PubMed ID: 12442990
[TBL] [Abstract][Full Text] [Related]
2. Assessing human health response in life cycle assessment using ED10s and DALYs: part 2--Noncancer effects.
Pennington D; Crettaz P; Tauxe A; Rhomberg L; Brand K; Jolliet O
Risk Anal; 2002 Oct; 22(5):947-63. PubMed ID: 12442991
[TBL] [Abstract][Full Text] [Related]
3. Approaches to cancer assessment in EPA's Integrated Risk Information System.
Gehlhaus MW; Gift JS; Hogan KA; Kopylev L; Schlosser PM; Kadry AR
Toxicol Appl Pharmacol; 2011 Jul; 254(2):170-80. PubMed ID: 21034767
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cancer slope factors using different statistical approaches.
Subramaniam RP; White P; Cogliano VJ
Risk Anal; 2006 Jun; 26(3):825-30. PubMed ID: 16834636
[TBL] [Abstract][Full Text] [Related]
5. US EPA's IRIS pilot program: establishing IRIS as a centralized, peer-reviewed data base with agency consensus. Integrated Risk Information System.
Mills A; Foureman GL
Toxicology; 1998 May; 127(1-3):85-95. PubMed ID: 9699796
[TBL] [Abstract][Full Text] [Related]
6. Topics in cancer risk assessment.
Olin SS; Neumann DA; Foran JA; Scarano GJ
Environ Health Perspect; 1997 Feb; 105 Suppl 1(Suppl 1):117-26. PubMed ID: 9114281
[TBL] [Abstract][Full Text] [Related]
7. What to do at low doses: a bounding approach for economic analysis.
Griffiths CW; Dockins C; Owens N; Simon NB; Axelrad DA
Risk Anal; 2002 Aug; 22(4):679-88. PubMed ID: 12224742
[TBL] [Abstract][Full Text] [Related]
8. Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: an analysis of pooled data for acrylonitrile-induced brain tumors to assess cancer potency in the rat.
Kirman CR; Hays SM; Kedderis GL; Gargas ML; Strother DE
Risk Anal; 2000 Feb; 20(1):135-51. PubMed ID: 10795346
[TBL] [Abstract][Full Text] [Related]
9. U.S. EPA's IRIS assessment of 2-butoxyethanol: the relationship of noncancer to cancer effects.
Gift JS
Toxicol Lett; 2005 Mar; 156(1):163-78. PubMed ID: 15705494
[TBL] [Abstract][Full Text] [Related]
10. Life cycle impact assessment: a challenge for risk analysts.
Matthews HS; Lave L; MacLean H
Risk Anal; 2002 Oct; 22(5):853-60. PubMed ID: 12442984
[TBL] [Abstract][Full Text] [Related]
11. Integrating site-specific dispersion modeling into life cycle assessment, with a focus on inhalation risks in chemical production.
Tian S; Bilec M
J Air Waste Manag Assoc; 2018 Nov; 68(11):1224-1238. PubMed ID: 29985784
[TBL] [Abstract][Full Text] [Related]
12. Significant shortcomings of the U.S. Environmental Protection Agency's latest draft risk characterization for dioxin-like compounds.
Starr TB
Toxicol Sci; 2001 Nov; 64(1):7-13. PubMed ID: 11606796
[TBL] [Abstract][Full Text] [Related]
13. Development of the method and U.S. normalization database for Life Cycle Impact Assessment and sustainability metrics.
Bare J; Gloria T; Norris G
Environ Sci Technol; 2006 Aug; 40(16):5108-15. PubMed ID: 16955915
[TBL] [Abstract][Full Text] [Related]
14. Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk.
Kavlock R; Dix D
J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):197-217. PubMed ID: 20574897
[TBL] [Abstract][Full Text] [Related]
15. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.
Gaylor DW; Swirsky Gold L
Regul Toxicol Pharmacol; 1998 Dec; 28(3):222-5. PubMed ID: 10049793
[TBL] [Abstract][Full Text] [Related]
16. Reducing uncertainty in risk assessment by using specific knowledge to replace default options.
McClellan RO
Drug Metab Rev; 1996; 28(1-2):149-79. PubMed ID: 8744594
[TBL] [Abstract][Full Text] [Related]
17. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
Davis JA; Gift JS; Zhao QJ
Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
[TBL] [Abstract][Full Text] [Related]
18. [Environment and health in Gela (Sicily): present knowledge and prospects for future studies].
Musmeci L; Bianchi F; Carere M; Cori L
Epidemiol Prev; 2009; 33(3 Suppl 1):7-12. PubMed ID: 19776462
[TBL] [Abstract][Full Text] [Related]
19. Human health effects of dichloromethane: key findings and scientific issues.
Schlosser PM; Bale AS; Gibbons CF; Wilkins A; Cooper GS
Environ Health Perspect; 2015 Feb; 123(2):114-9. PubMed ID: 25325283
[TBL] [Abstract][Full Text] [Related]
20. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
